Tumor-Associated Antigen Identification via Gene Expression Profiling
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for identifying tumor-associated antigens often use immunoeffectors from patients with advanced cancer, which may lead to tolerization and loss of effective immune recognition specificities, making it unclear if targeted proteins evoke spontaneous immune responses.
Innovation Solution
Identification of genes selectively or aberrantly expressed in tumor cells, providing tumor-associated antigens that can be used as target structures for therapeutic and diagnostic approaches, including their nucleic acids, proteins, and derivatives, along with antibodies and T cells directed against them.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If classical methods using immunoeffectors from patients with advanced cancer are used to identify tumor-associated antigens, then antigen identification can be performed, but the immune system may become tolerized and lose effective immune recognition specificities
Solution Approach 1:
The patent applies preliminary action by identifying and characterizing tumor-associated antigens in tumor cells before using them for therapeutic purposes. The method involves systematically analyzing tumor cell gene expression profiles to identify antigens that are selectively or aberrantly expressed, thereby establishing reliable target structures for therapy before the patient's immune system becomes tolerized during advanced disease stages.
2Ease of manufacture
If tumor-associated antigens are identified using immunoeffectors from advanced cancer patients, then antigen targeting can be achieved, but it becomes unclear whether the targeted proteins evoke spontaneous immune responses
Solution Approach 1:
The patent uses copying by creating a systematic profile of tumor cell gene expression and identifying antigens based on their selective or aberrant expression patterns. This approach copies the essential characteristic of tumor cells (aberrant gene expression) to identify target antigens, thereby establishing reliable targets for therapy without relying on potentially compromised immunoeffectors from advanced patients.
Data Source
AI summary
The invention relates to genetic products the expression of which is associated with cancer diseases. The invention also relates to the therapy and diagnosis of diseases in which the genetic products are expressed or aberrantly expressed, in particular cancer diseases.